Business
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active comparator in IgA nephropathy (IgAN), at the 60th ERA Congress in Milan, Italy, June 15-18, 2023. Also included in the presentations is a new analysis of the UK RaDaR Registry estimating the delay in time to kidney failure or death based on proteinuria reduction in IgAN, which has been designated among the 10 best-ranked abstracts of 2023 by ERA. “We’re pleased to bring to the ERA Congress the strong interim results from our ongoing PROTECT Study which demonstrate that sparsentan significantly reduces proteinuria in IgA nephropathy,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. “We also look forward to sharing more data from the IgA nephropathy field showing the relationship between reducing proteinuria in IgA nephropathy and preservation of kidney function.” Mini-Lecture Presentations Estimating Delay in Time to Kidney Failure or Death for Treatment Effects on Proteinuria in IgA NephropathySession: The Art of Staring at Urine: Studies in IgA NephropathyLocation & Time: Brown 1 & 2; Friday, June 16, 2023, 12:34 – 12:47 p.m. CEST*Among the 10 best-ranked abstracts of ERA Congress 2023 Superior Proteinuria Reduction with Sparsentan in Immunoglobulin A Nephropathy (IgAN): PROTECT Study Interim AnalysisSession: The Art of Staring at Urine: Studies in IgA NephropathyLocation & Time: Brown 1 & 2, Friday, June 16, 2023, 1 - 1:15 p.m. CEST Modeling Long-term Outcomes for Patients with Immunoglobulin A Nephropathy (IgAN) from Short-term Proteinuria DataSession: Navigating the IgA Nephropathy PathwayLocation & Time: Amber 1 & 2, Saturday, June 17, 2023, 3:45 - 4:00 p.m. CEST Alport Syndrome Natural History from the RaDaR Registry: Associations with Gene, Variant Type and SexSession: Small Patients, Big DataLocation & Time: Brown 1 & 2; Friday, June 16, 2023, 5:34 - 5:47 p.m. CEST Moderated Oral Presentation Outcomes in SRNS (FSGS) Patients in the UK RaDaR Idiopathic Nephrotic Syndrome Registry and Their Relationship with Time-Averaged ProteinuriaSession: Moderated Orals 2.3Location & Time: Amber 6; Saturday, June 17, 2023, 2:57...